Benzinga

Benzinga

Benzinga

sábado, septiembre 05

Stoke Therapeutics Inc

STOKNASDAQ
Trade with Public
Trade with Public
$29.81
-0.18-0.6%
al cierre: Sep 4, 5:00 PM EST
$29.81
N/A
After hour: 4:00 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Stoke Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Stoke Therapeutics (STOK).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

13Buy
Consensus RatingBuy# Analysts13Avg. Consensus PT$41Upside to Avg. PT+38.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 21, 2026JP MorganJessica FyeReinstatesOverweight$40
Aug 4, 2026GuggenheimYatin SunejaMaintainedBuy$60
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price Target

JP Morgan analyst Jessica Fye reinstates Stoke Therapeutics (NASDAQ:STOK) with a Overweight and announces $40 price target.
Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on Stoke Therapeutics, Maintains $60 Price Target

Guggenheim analyst Yatin Suneja reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $60 price target.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $40

Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $38 to $40.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Stoke Therapeutics, Lowers Price Target to $58

Canaccord Genuity analyst Sumant Kulkarni maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and lowers the price target from $60 to $58.
Benzinga Newsdesk

PRO
Goldman Sachs Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $44

Goldman Sachs analyst Kevin Strang initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a Buy rating and announces Price Target of $44.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Stoke Therapeutics, Maintains $39 Price Target

BTIG analyst Thomas Shrader reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $39 price target.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved